TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28656047

Group type: EXPERIMENTAL
Intervention: No antimicrobial prophylaxis (AMP)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Per-protocol analysis (excluding 44 patients with protocol violations)
Number of subjects: 105
Study: 28656110

Group type: EXPERIMENTAL
Intervention: 2G (760 mg of n-3 FA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3G (1140 mg of n-3 FA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (5 athletes and 4 training staff volunteers)
Number of subjects: 24
Study: 28656468

Group type: EXPERIMENTAL
Intervention: Self-administered implementation intention group
Number of subjects: 423

Group type: COMPARATOR
Intervention: Standard physical activity recommendation group
Number of subjects: 423

Group type: COMPARATOR
Intervention: Telephone-assisted implementation intention group
Number of subjects: 423
Study: 28657510

Group type: EXPERIMENTAL
Intervention: Screening with neck ultrasound and fine-needle aspiration biopsy
Number of subjects: 109
Study: 28657941

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with pathologic complete response (pCR)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with residual disease
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with pCR and residual disease
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 701
Study: 28658601

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measured by dual energy X-ray absorptiometry expressed as T- and Z-scores.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Markers of bone remodelling processes (CTX, BSAP, osteocalcin).
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Osteoporotic fractures identified by X-ray.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Vitamin D levels.
Number of subjects: 96
Study: 28659176

Group type: EXPERIMENTAL
Intervention: ISOWN algorithm for somatic mutation identification
Number of subjects: 1600
Study: 28659258

Group type: EXPERIMENTAL
Intervention: Wearable sensors (specific devices not mentioned)
Number of subjects: 0
Study: 28659296

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28659297

Group type: EXPERIMENTAL
Intervention: Nutritional strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gut microbiota composition
Number of subjects: 0
Study: 28659298

Group type: EXPERIMENTAL
Intervention: Nutritional metabolomics
Number of subjects: 0
Study: 28659301

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28659784

Group type: EXPERIMENTAL
Intervention: Assist-as-needed (AAN) robotic controller
Number of subjects: 17

Group type: COMPARATOR
Intervention: Subject-triggered (ST) controller
Number of subjects: 17
Study: 28659869

Group type: EXPERIMENTAL
Intervention: Short-term continuous training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval-type training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer term interval training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with reduction in fat mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline total body mass (TBM), fat-free mass (FFM), and fat mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in TBM and fat mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in physical fitness, glycemic control, or FFM
Number of subjects: 0
Study: 28659913

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28660118

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 28660276

Group type: EXPERIMENTAL
Intervention: Retinotopic electrode mapping
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nonretinotopic electrode mapping
Number of subjects: 3
Study: 28660406

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER) 6 mg/day, titrated between 1.5 and 12 mg/day based on clinical response and tolerability
Number of subjects: 400
Study: 28660564

Group type: EXPERIMENTAL
Intervention: Smartphone application "Optisizer" for measuring body length
Number of subjects: 627

Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 627

Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 627

Group type: COMPARATOR
Intervention: Parents
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Smartphone application "Optisizer"
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Real length categories
Number of subjects: 627
Study: 28660668

Group type: EXPERIMENTAL
Intervention: Two-steps method for capturing hallucinatory events using fMRI
Number of subjects: 85
Study: 28661382

Group type: EXPERIMENTAL
Intervention: Let's Go program
Number of subjects: 52
Study: 28662033

Group type: EXPERIMENTAL
Intervention: Pazopanib + escalating doses of 131I
Number of subjects: 6
Study: 28662235

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with metronomic cyclophosphamide (50 mg cyclophosphamide twice daily, 200 mg pembrolizumab every 3 weeks)
Number of subjects: 57
Study: 28662513

Group type: EXPERIMENTAL
Intervention: T-lymphocytes involvement in AKI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental AKI studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limited human data
Number of subjects: 0
Study: 28662684

Group type: EXPERIMENTAL
Intervention: Continuous high-intensity interval cycle ergometer exercises with short-acting insulin doses reduced by 25%, 50%, and 75%.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Continuous high-intensity interval cycle ergometer exercises with varying intensities set at 5% below and 5% above the first lactate turn point and 5% below the second lactate turn point.
Number of subjects: 1
Study: 28662805

Group type: EXPERIMENTAL
Intervention: Increasing hospital TAVR volume
Number of subjects: 42988

Group type: EXPERIMENTAL
Intervention: Transfemoral access subgroup
Number of subjects: 42988
Study: 28662806

Group type: EXPERIMENTAL
Intervention: FRANCE TAVI
Number of subjects: 12804
Study: 28662936

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (ARNI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study: 28663190

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 28663822

Group type: EXPERIMENTAL
Intervention: Food reward sensitivity
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Behavioral control
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Home food environment
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Maternal diet quality
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Gestational weight gain
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Postpartum weight retention
Number of subjects: 450
Study: 28664499

Group type: EXPERIMENTAL
Intervention: Romidepsin 9 mg/m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romidepsin 14 mg/m²
Number of subjects: 0
Study: 28664507

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET) in RS ≤ 11 patients
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Chemotherapy (anthracycline-containing or anthracycline-free) in RS 12-25 patients
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Chemotherapy (anthracycline-containing or anthracycline-free) in RS > 25 patients
Number of subjects: 3198
Study: 28665051

Group type: EXPERIMENTAL
Intervention: Veliparib 200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Veliparib 400 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study: 28665197

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28666281

Group type: EXPERIMENTAL
Intervention: Increased FAF spots (36 areas from 15 eyes)
Number of subjects: 134
Study: 28666775

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7028

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7028

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7028
Study: 28666990

Group type: EXPERIMENTAL
Intervention: AF gene score (GS) calculated from 7 genes upregulated in AF
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Biological age gene score based on 1254 genes related to aging
Number of subjects: 416
Study: 28667381

Group type: EXPERIMENTAL
Intervention: Prandial premixed therapy (PPT) - insulin lispro mix 50/50 thrice daily with meals
Number of subjects: 182

Group type: COMPARATOR
Intervention: Basal-bolus therapy (BBT) - glargine at bedtime plus mealtime insulin lispro
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Overall at-goal patients (PPT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Overall at-goal patients (BBT)
Number of subjects: 182
Study: 28667563

Group type: EXPERIMENTAL
Intervention: Progressive machine-based resistance training (RT, 12 weeks, 2×/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Treatment as usual (CON)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Progressive machine-based resistance training (RT)
Number of subjects: 10
Study: 28667569

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day for 104 weeks
Number of subjects: 314
Study: 28667887

Group type: EXPERIMENTAL
Intervention: Low Amplitude Seizure Therapy (LAP-ST, 0.5-0.6A)
Number of subjects: 22
Study: 28668090

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O) prescribed to patients with PF
Number of subjects: 20
Study: 28668141

Group type: EXPERIMENTAL
Intervention: hs-cTn concentrations ≥ 14 ng/L
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Different hs-cTnT/hs-cTnI concentration ranges
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Common low-risk cutoff of 14 ng/L
Number of subjects: 1137
Study: 28668244

Group type: EXPERIMENTAL
Intervention: Sublingual allergen-specific immunotherapy (SLIT) with Staloral 300 SR Der p and Der f 50/50% extract
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sublingual allergen-specific immunotherapy (SLIT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 28668356

Group type: EXPERIMENTAL
Intervention: Any acute exacerbation over 3 years
Number of subjects: 1105

Group type: COMPARATOR
Intervention: No acute exacerbations
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: At least one acute exacerbation each year
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Two or more acute exacerbations each year
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Inconsistent exacerbation pattern
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: GOLD stages 3 and 4 patients
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Consistent acute exacerbations (≥1 event per year for 3 years)
Number of subjects: 1105
Study: 28668546

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study: 28668768

Group type: EXPERIMENTAL
Intervention: Poor brain tissue oxygenation (BtO) during the first 24 hours of critical illness
Number of subjects: 0
Study: 28669012

Group type: EXPERIMENTAL
Intervention: Lapatinib (2500 mg twice daily for two consecutive days per week)
Number of subjects: 12
Study: 28669844

Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Quinolone resistance
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Overall clarithromycin resistance
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Overall quinolone resistance
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Detection of both sensitive and resistant H. pylori
Number of subjects: 2004
Study: 28669895

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVU)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Modified hysterosalpingogram (HSG)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Confirmation testing algorithm (TVU and/or modified HSG)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 597
Study: 28670237

Group type: EXPERIMENTAL
Intervention: Adalimumab (160 mg at week 0, 80 mg at week 2, 40 mg every other week thereafter)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 20
Study: 28670355

Group type: EXPERIMENTAL
Intervention: Non-thermal laser therapy
Number of subjects: 0
Study: 28673311

Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS) for multi-pad stimulation electrode shaping
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) using DSS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DSS in combination with a custom multi-pad electrode design
Number of subjects: 10
Study: 28673924

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0
Study: 28674057

Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 600 mg and maintenance dose (MD) of 400 mg for ECMO patients not receiving continuous renal replacement therapy (CRRT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 800 mg and maintenance dose (MD) of 600 mg for ECMO patients receiving CRRT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 1,000 mg and maintenance dose (MD) of 800 mg for ECMO patients not receiving CRRT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 1,200 mg and maintenance dose (MD) of 1,000 mg for ECMO patients receiving CRRT
Number of subjects: 10
Study: 28674140

Group type: EXPERIMENTAL
Intervention: BTT1023 (anti-VAP monoclonal antibody)
Number of subjects: 59
Study: 28674838

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Laparoscopic Greater Curvature Plication (LGCP)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Both LSG and LGCP
Number of subjects: 127
Study: 28674870

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (doses converted to haloperidol equivalents)
Number of subjects: 31
Study: 28674982

Group type: EXPERIMENTAL
Intervention: Traditional pharmaceuticals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisense therapies targeting familial forms of ALS
Number of subjects: 0
Study: 28675064

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) subjects
Number of subjects: 237

Group type: COMPARATOR
Intervention: Cardiac syndrome X (CSX) subjects
Number of subjects: 237
Study: 28675524

Group type: EXPERIMENTAL
Intervention: Fecal markers and plasma citrulline measured in hypersensitive IBS patients (n=83)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Fecal markers and plasma citrulline measured in normosensitive IBS patients (n=84)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma for serotonin and 5-HIAA in hypersensitive IBS patients (n=53)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Platelet-poor plasma for serotonin and 5-HIAA in normosensitive IBS patients (n=42)
Number of subjects: 167
Study: 28675695

Group type: EXPERIMENTAL
Intervention: Integrated psychological intervention (IPI) including cognitive behavioural therapy (CBT) and supportive counselling (SC) for 12 months
Number of subjects: 128
Study: 28676102

Group type: EXPERIMENTAL
Intervention: Interactive information and communications technology platform (app for reporting symptoms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 28676207

Group type: EXPERIMENTAL
Intervention: Diet elimination alone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Swallowed corticosteroids alone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Diet elimination and swallowed corticosteroids
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 123
Study: 28676450

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 5mg
Number of subjects: 197
Study: 28676651

Group type: EXPERIMENTAL
Intervention: D-dimer testing
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: D-dimer testing with a fixed threshold of 0.25 mg/L FEU
Number of subjects: 500

Group type: COMPARATOR
Intervention: D-dimer and CRP
Number of subjects: 500
Study: 28676782

Group type: EXPERIMENTAL
Intervention: Thought Field Therapy (TFT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-List Control
Number of subjects: 0
Study: 28676842

Group type: EXPERIMENTAL
Intervention: DBS plus optimal drug therapy (DBS+ODT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 29
Study: 28677510

Group type: EXPERIMENTAL
Intervention: Statin monotherapy
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Fibrate monotherapy
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Daily drug intake
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Higher levels of ApoA1
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Higher CV risk
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Forgot to take medication
Number of subjects: 3338

Group type: EXPERIMENTAL
Intervention: Stopped medication when cholesterol normal
Number of subjects: 3338
Study: 28678012

Group type: COMPARATOR
Intervention: Transperitoneal laparoscopic nephrectomy (Group T)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic nephrectomy (Group R)
Number of subjects: 40
Study: 28678647

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel, liquid cleanser, and moisturizer SPF 30
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel
Number of subjects: 50
Study: 28678771

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D <50 nmol/l)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D ≥75 nmol/l)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D 50-74.9 nmol/l)
Number of subjects: 568
Study: 28679361

Group type: EXPERIMENTAL
Intervention: Physical functioning
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Emotional health
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Social functioning
Number of subjects: 714
Study: 28679389

Group type: EXPERIMENTAL
Intervention: Family Planning (FP) use
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Use of long-acting reversible contraceptives or permanent methods (LARC-PM)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Predictors of long-term method use
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Qualitative data on contraceptive choices
Number of subjects: 240
Study: 28679598

Group type: EXPERIMENTAL
Intervention: MP-Ld (12.5 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MP-Hd (17.5 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: LD+DDCI (3.5 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LD-DDCI (17.5 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28679611

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28679644

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus Bevacizumab
Number of subjects: 30
Study: 28679676

Group type: EXPERIMENTAL
Intervention: Risk stratification pathway using transient elastography and hepatologists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 28680717

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg daily)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 28680917

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 552
Study: 28680916

Group type: EXPERIMENTAL
Intervention: Lipoic acid (LA) 1,200 mg daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 28680960

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 322
Study: 28681650

Group type: EXPERIMENTAL
Intervention: E6011 100 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: E6011 200 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: E6011 400 mg
Number of subjects: 37
Study: 28682105

Group type: EXPERIMENTAL
Intervention: Emotion regulation difficulties
Number of subjects: 90
Study: 28682697

Group type: EXPERIMENTAL
Intervention: Low-intensity activity breaks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate-intensity activity breaks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-intensity activity breaks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Screen-time breaks
Number of subjects: 39
Study: 28682736

Group type: EXPERIMENTAL
Intervention: Submaximal treadmill testing
Number of subjects: 0
Study: 28682807

Group type: EXPERIMENTAL
Intervention: New prediction model combining colonoscopic, laboratory, and radiologic parameters.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Colonoscopic scoring for differentiation.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CD prediction score (from -2 to 2).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve of the score.
Number of subjects: 80
Study: 28683470

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Model combining osteopontin, interleukin-6, TIMP-1, tumour burden, and selected clinical criteria
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 28683732

Group type: EXPERIMENTAL
Intervention: Common treatment regimens for AIS
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Different treatment regimens for AIS
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Adverse events and complications
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: TOAST classification
Number of subjects: 10000
Study: 28683743

Group type: EXPERIMENTAL
Intervention: Health literacy measured by the Newest Vital Sign (NVS)
Number of subjects: 247
Study: 28683745

Group type: EXPERIMENTAL
Intervention: Intensive therapeutic intervention for 12 weeks
Number of subjects: 30
Study: 28684262

Group type: EXPERIMENTAL
Intervention: Standardised solid test meal (STM) during high-resolution manometry (HRM)
Number of subjects: 750